SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
P/B ratio for SIGA Technologies, Inc. (SIGA)
P/B ratio as of 2023: 2.03
According to SIGA Technologies, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.03. At the end of 2022 the company had a P/B ratio of 3.15.
P/B ratio history for SIGA Technologies, Inc. from 1996 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.03 |
| 2022 | 3.15 |
| 2021 | 3.25 |
| 2020 | 4.44 |
| 2019 | 3.95 |
| 2018 | 6.14 |
| 2017 | -1.18 |
| 2016 | -0.57 |
| 2015 | -0.08 |
| 2014 | -0.31 |
| 2013 | 10.03 |
| 2012 | 4.67 |
| 2011 | 3.08 |
| 2010 | 52.38 |
| 2009 | 20.72 |
| 2008 | 73.06 |
| 2007 | 19.64 |
| 2006 | 14.52 |
| 2005 | 7.30 |
| 2004 | 8.64 |
| 2003 | 6.48 |
| 2002 | 6.88 |
| 2001 | 6.96 |
| 2000 | 24.61 |
| 1999 | 4.87 |
| 1998 | 1.68 |
| 1997 | 1.70 |
| 1996 | 40.25 |